---
schema_version: "secwatch.filing_event.v1"
accession: "0001714899-26-000036"
form_type: "8-K"
ticker: "DNLI"
cik: "0001714899"
company_name: "Denali Therapeutics Inc."
filed_at: "2026-03-31T23:59:59+00:00"
generated_at: "2026-05-15T08:11:42.961116+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Denali Therapeutics receives $200M from Royalty Pharma after FDA approval of tividenofusp alfa

## Summary
- Received $200.0M gross proceeds from Royalty Pharma under synthetic royalty funding agreement.
- Closing followed FDA accelerated approval of tividenofusp alfa on March 24, 2026.
- Synthetic royalty agreement was previously announced on December 4, 2025.
- Proceeds provide non-dilutive capital for further development and commercialization.

## SEC filing metadata
- accession: 0001714899-26-000036
- form_type: 8-K
- ticker: DNLI
- cik: 0001714899
- company_name: Denali Therapeutics Inc.
- filed_at: 2026-03-31T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.03, 1.01, 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1714899/000171489926000036/0001714899-26-000036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1714899/000171489926000036/dnli-20260327.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001714899-26-000036
- JSON: https://secwatch.observer/filing/0001714899-26-000036.json
- Plain text: https://secwatch.observer/filing/0001714899-26-000036.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.